Abstract
Chinese drug legislation, enacted in 1985, requires that new drugs be approved by the national drug regulatory authority before they can be marketed in China. Since enactment of this legislation, China has significantly improved its regulatory review process for new drugs. During the same time period, the pharmaceutical industry in China has shown considerable expansion. With China’s membership in the World Trade Organization, the Chinese pharmaceutical industry is experiencing change and will continue to do so. The new Drug Registration Regulation, which is compatible with the World Trade Organization agreement, went into effect on December 1, 2002. This paper reviews China’s new drug approval history, regulatory policy and administration, and related issues with respect to China’s climate for pharmaceutical innovation and the Chinese pharmaceutical industry. We provide approval data for new chemical entities (NCEs) approved from 1985 through 2000, and draw a picture of China’s NCE review policies and the NCE approval process. We also offer views on changes to China’s environment for pharmaceutical innovation since joining the World Trade Organization.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Inf J. 2000;34(1):1–14.
Drug Administrative Law. Beijing, China: National Law of the People’s Republic of China: 1985.
Ministry of Health, China. Provisions for New Drug Approval. Beijing, China: Ministry of Health; 1985.
Ministry of Health, China. Provisions for New Biological Product Approval. Beijing, China: Ministry of Health: 1985.
Ministry of Health, China. Provisions for Importation Registration. Beijing, China: Ministry of Health; 1991.
State Drug Administration, China. Provisions for Importation Registration. Beijing, China: State Drug Administration; 1999.
State Pharmaceutical Administration of China. Provisions for Drug Administration Protection. Beijing, China: Stale Medical and Drug Administration Bureau; 1993.
State Drug Administration, China. Provisions for New Drug Approval. Beijing, China: State Drug Administration; 1999.
State Drug Administration, China. Drug Registration Procedure. Beijing, China: State Drug Administration; 2000.
Center for Drug Evaluation, China. National new drug registration database, 2001. www.cde.org.cn.
State Drug Administration. Administrative protection approvals: 1993–2000. www.sda.gov.cn.
Summary of the National Pharmaceutical Administration in 2001. Xinhua News Agency. big5.xinhuanet.com/gate/big5/news.xinhuanet.com/zhengfu/2002-02/07/content_272025.htm. Accessed May, 2, 2002.
US Department of Commerce, International Trade Administration. Pharmaceutical industry fact sheet: China. www.mac.doc.gov/China/Docs/industryfactsheets/pharmaceulicals.html. Accessed May 24, 2002.
Hamrock S, Whiting. C, Blaha C, Clark H, Lashley D, Market access and compliance: what it means for U.S. industry. www.mac.doc.gov/China/Docs/exportamerica/WTOChina.html. Accessed May 24, 2002.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ms. Deng is Senior officer at the Sichuan Drug Administration, Chengdu, China. She conducted this research while on a two-year World Health Organisation fellowship at the Tufts Center for the Study of Drug Development.
Rights and permissions
About this article
Cite this article
Deng, R., Kaitin, K.I. The Regulation and Approval of New Drugs in China. Ther Innov Regul Sci 38, 29–39 (2004). https://doi.org/10.1177/009286150403800105
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150403800105